UK Hereditary Angioedema Launch Readiness

Lanadelumab (Takhzyro, Takeda) is NHS England's commissioned HAE prophylaxis standard via NICE TA606, delivered subcutaneously and priced with a confidential PAS estimated at 50-60% off a ~£45,000/year UK WAC. It is entrenched at NHS specialist HAE centres (Sheffield, Cambridge, Birmingham, Guy's and St Thomas', Manchester) which manage over 90% of UK HAE patients. But entrenchment is not saturation: of an estimated 5,000-6,000 UK HAE patients, only 1,500-2,000 are on prophylaxis. Between 1,500 and 2,500 attack-active patients (≥3 attacks/year) have never been prophylaxed, held back less by clinical eligibility than by NHS specialist-centre capacity and an 8-10 year mean diagnostic delay — one of the longest in the developed world, driven by GP unfamiliarity with angioedema presenting without urticaria.

For a new oral prophylaxis entrant, growing the market is the more tractable strategy than displacing lanadelumab in stable patients, and it mirrors how berotralstat (Orladeyo, BioCryst) entered the US. Berotralstat already cleared NICE as TA738 (2021), recommended for patients with 2 or more attacks per month, and has held the UK's first and only oral-prophylaxis slot for nearly five years. Donidalorsen (Ionis Pharmaceuticals), an antisense oligonucleotide dosed subcutaneously, reported an 81% attack-rate reduction in the Phase 3 OASIS-HAE trial and is expected to file with the MHRA in 2024-2025 and reach NICE 12-18 months after, putting a clinically strong SC competitor on a collision course with any new entrant targeting the injectable segment. NICE's HAE pathway is standard technology appraisal (HAE is too common for HST), applying the ordinary £20,000-30,000/QALY threshold; lanadelumab's own QALY gain of 0.15-0.25/year against its UK WAC required a 50-60% PAS to clear that bar.

The pre-launch sequence: apply for MHRA's Innovative Licensing and Access Pathway (ILAP) roughly 24 months ahead of submission to align regulatory and NICE evidence expectations early — particularly urgent given donidalorsen's parallel UK timeline. Model an oral WAC of £25,000-35,000/year with a 25-40% PAS, which reaches NICE-viability without the depth of discount lanadelumab required, and credit the QALY model with the administration-cost saving of an oral agent over lanadelumab's SC nurse-administration pathway. Sponsor the UK HAE Alliance's patient-experience survey and NICE patient group submission roughly 12 months ahead of filing, and engage the BSACI HAE guideline committee 18-24 months pre-submission; UK clinical guidelines shape NHS prescribing ahead of any NICE decision.

This assessment synthesises three research angles into a single UK HAE launch readiness view: competitive positioning against lanadelumab and berotralstat, never-prophylaxed population sizing anchored in the UK HAE Alliance patient census, and anticipated NICE/NHS payer posture derived from the TA606 lanadelumab precedent.

Sources: NICE TA606 lanadelumab decision document; NICE TA738 berotralstat decision document; UK HAE Alliance patient census and diagnostic-delay survey; BSACI HAE clinical guidelines; Ionis Pharmaceuticals donidalorsen OASIS-HAE data (NEJM 2024); NHS England HAE specialised service specification.